New medical technology

Sinopharm group has made a major discovery that delta mutant strain is expected to usher in specific drugs!

  Sinopharm group has made a major discovery that delta mutant strain is expected to usher in specific drugs! On August 4, cnbg announced that Yang Xiaoming, a researcher of Sinopharm group, had recently found an effective monoclonal antibody against delta variant strain, with the and activity IC50 as high as 5ng / ml. This means that novel coronavirus pneumonia is effective in the presence of monoclonal antibodies, and is expected to usher in a specific therapeutic effect against new strains of crown pneumonia, especially the delta strain. The research results have been published online in cell discovery, a subsidiary of nature. At present, the clinical declaration of the antibody is advancing in an orderly way, and is expected to be used in the prevention and control of COVID-19 in China.

  Monoclonal antibodies, as targeted therapeutic drugs, are known as & ldquo; Biological missile;, It shows excellent curative effect and broad application prospect in the treatment of a variety of diseases. In response to viral infectious diseases, neutralizing monoclonal antibodies can specifically neutralize virus and prevent virus from entering cell proliferation. It can be used as a short-term prevention for high-risk groups, and can also be used for the treatment of viral infections. Therefore, it is also a hot topic in global COVID-19 prevention and control research.

  In this study, phage display technology was used to construct peripheral blood mononuclear cells (PBMC) from 8 COVID-19 infected patients, and the immunization library was established. A number of monoclonal antibodies with high activity and high activity to COVID-19 were successfully screened out. The crystal structure analysis data show that the RBD epitope recognized by the most active antibody 2B11 is highly overlapped with the binding site of ACE2, which can effectively block the binding of COVID-19 to the ACE-2 on the cell surface, thereby preventing its infected cells.

  Meanwhile, the team also used hACE2- adenovirus (hACE2-ADV) transduced IFNAR-/- mouse model to evaluate the preventive and therapeutic effects of 2B11 on COVID-19 infection. The results showed that compared with the control group, 2B11 administration before or after challenge could significantly reduce the weight loss and pulmonary viral load caused by virus infection; Further analysis of lung pathological sections showed that the application of 2B11 could significantly reduce the lung inflammation caused by virus infection.

  According to the B.1.617.2 novel coronavirus pneumonia variant, which has become the main variant of the new global crown pneumonia, the recent research results showed that 2B11 had a high level of neutralization activity to the mutant strain. It indicates that novel coronavirus pneumonia caused by delta strain is of great value in short-term prevention and early treatment of 2B11.

More information, please pay attention to EVO WeChat official account.

Pre:Who: we welcome the preliminary results of dexamethasone in the treatment of 2019 severe patients with coronavirus disease, but the drug is not suitable for mild disease or prevention

Next:China scientists report: COVID-19 RNA does not have the ability to integrate into the host genome.